IOMAI

IOMAI was a biotechnology company founded in 1997 by Gregory Glenn, M.D., of the Walter Reed Army Institute of Research and Dean Lewis, a World Bank employee. The company focused on a distinctive vaccine-delivery concept: transcutaneous immunization, in which an antigen or vaccine-related adjuvant is delivered to the skin rather than administered solely through a conventional hypodermic injection. The scientific premise behind IOMAI's work was that the skin is an immunologically active organ. In particular, skin-resident Langerhans cells can process antigen and help initiate an immune response. IOMAI developed patch-based approaches intended to exploit this biology, with the potential to stimulate strong immune responses while reducing reliance on needles. The company's work helped distinguish transcutaneous immunization from other needle-free or minimally invasive approaches, including intradermal injection and broader transdermal delivery technologies. IOMAI's most visible development program involved a vaccine patch for travelers' diarrhea caused by enterotoxigenic Escherichia coli, or ETEC. The approach used heat-labile toxin, or LT, as an immunological component and explored skin pretreatment to improve delivery through the outer skin barrier. Published clinical work reported studies of safety, immunogenicity, protective efficacy, and field performance. A phase II field trial examining an LT-containing patch was reported in The Lancet in 2008, and the program subsequently entered pivotal phase III trials in 2009 according to the company's Wikipedia account. The company's research also extended to influenza vaccination and other applications of skin-targeted immunization. Published studies examined an LT adjuvant patch used with an H5N1 influenza vaccine and investigated intradermal influenza vaccination as a dose-sparing strategy. These studies contributed to wider scientific interest in adjuvant patches, skin pretreatment, and immunization methods designed to target antigen-presenting cells in the skin. IOMAI was acquired by Intercell in 2008. Following the acquisition, the technology was the subject of a development license granted to GlaxoSmithKline in 2009. These transactions marked a shift from IOMAI as an independent biotechnology company toward the use and further development of its technology within larger vaccine organizations. The available reference material does not establish that an IOMAI-branded commercial vaccine reached the market. IOMAI is therefore best understood historically as a biotechnology innovator and platform developer rather than as a current consumer-facing vaccine brand.

IOMAI was established in 1997 by Gregory Glenn, M.D., associated with the Walter Reed Army Institute of Research, and Dean Lewis, who was associated with the World Bank. From its inception, the company concentrated on transcutaneous immunization: the delivery of vaccine antigens or immunologically active substances through the skin with a patch or comparable application rather than through a standard injection. The company's approach was based on the immunological properties of the skin. IOMAI's research treated the skin as an active site for vaccination because it contains Langerhans cells and other antigen-presenting structures capable of initiating immune responses. This approach sought to combine the convenience of a patch with the possibility of generating robust immunity. It also placed IOMAI within a broader scientific effort to develop needle-free vaccination, intradermal administration, and improved vaccine adjuvants. A central development program targeted travelers' diarrhea associated with enterotoxigenic Escherichia coli. The program used heat-labile toxin, commonly abbreviated LT, in a patch-based immunization strategy. Research examined whether pretreatment of the skin could disrupt the stratum corneum and improve delivery, while clinical studies evaluated the safety and immunogenicity of the approach. A double-blind, placebo-controlled field study published in 2008 assessed an LT-containing patch in the context of travelers' diarrhea. Earlier publications also reported protective efficacy in a controlled challenge study and investigated the biological and practical requirements for transcutaneous administration. IOMAI's research portfolio was not limited to one pathogen. Published work examined the use of a heat-labile enterotoxin adjuvant patch alongside an H5N1 influenza vaccine and explored whether intradermal influenza vaccination could reduce the amount of vaccine required. These studies helped draw attention to skin-targeted vaccination, adjuvant patches, and alternative routes of immunization. The company's work also contributed to general interest in needle-free delivery and in targeting immune cells located in the skin. In 2008, Intercell acquired IOMAI. This transaction ended IOMAI's period as an independent biotechnology company and transferred its platform and development programs to the acquiring organization. In 2009, the technology was the subject of a development license to GlaxoSmithKline. During the same period, the travelers' diarrhea vaccine patch was reported to have entered phase III pivotal trials. The available material does not document regulatory approval or commercialization of an IOMAI-branded product. Consequently, IOMAI's historical importance rests primarily on its platform science and its role in advancing transcutaneous immunization, rather than on a currently marketed product portfolio.

• 2009

  Travelers' diarrhea program reaches phase III

  [1]IOMAIen.wikipedia.org

  The travelers' diarrhea vaccine patch entered pivotal phase III trials, according to the IOMAI reference article.

• 2009

  Technology licensed for development to GlaxoSmithKline

  [1]IOMAIen.wikipedia.org

  IOMAI's technology was made subject to a development license to GlaxoSmithKline.

• 2008

  Intercell acquires IOMAI

  [1]IOMAIen.wikipedia.org

  Intercell acquired IOMAI and its vaccine-patch and transcutaneous immunization technology.

• 2008

  Travelers' diarrhea patch field trial published

  [2]Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoeadoi.org

  The Lancet published results from a randomized, double-blind, placebo-controlled field trial of a heat-labile-toxin patch against travelers' diarrhea.

• 2007

  ETEC patch studies report immunogenicity and protective efficacy

  [1]IOMAIen.wikipedia.org

  Clinical publications described safety, immune responses, and protective efficacy associated with an ETEC vaccine approach using heat-labile toxin and transcutaneous delivery.

• 2004

  Intradermal influenza dose-sparing research published

  [6]Dose sparing with intradermal injection of influenza vaccinedoi.org

  A published study examined whether intradermal administration could reduce the dose required for influenza vaccination, contributing to the broader scientific case for skin-targeted immunization.

• 1997

  IOMAI founded

  [1]IOMAIen.wikipedia.org

  Gregory Glenn, M.D., and Dean Lewis founded IOMAI as a biotechnology company focused on skin-based vaccine delivery.

IOMAI positioned itself around needle-free or minimally invasive immunization, using the immune functions of the skin to deliver vaccines and adjuvants. Its work emphasized vaccine dose efficiency, skin targeting, and the possibility of safer and more practical vaccination without conventional injections.

• Vaccine candidate

  ETEC travelers' diarrhea vaccine patch

  A patch-based vaccine candidate designed to protect against travelers' diarrhea associated with enterotoxigenic Escherichia coli. The program used heat-labile toxin in a transcutaneous immunization approach and was evaluated in clinical studies, including field and challenge studies. It progressed to pivotal phase III trials in 2009, but the available reference material does not establish final regulatory approval or commercial launch.

• Vaccine-delivery technology

  Transcutaneous immunization platform

  IOMAI's core platform delivered vaccine-related material to the skin using a patch or similar method. The approach sought to stimulate Langerhans cells and other immune mechanisms in the skin, providing a needle-free or reduced-needle alternative to conventional vaccination. The platform was applied to infectious-disease vaccine research and helped stimulate wider interest in skin-targeted immunization.

• Vaccine adjuvant

  Heat-labile toxin adjuvant patch

  A skin-applied patch using heat-labile toxin from enterotoxigenic E. coli as an immunological adjuvant or vaccine component. Research investigated its ability to enhance immune responses when used in transcutaneous immunization and alongside other vaccine antigens, including an H5N1 influenza vaccine.

• 2009

  Development license to GlaxoSmithKlineOther

  Background

  Following Intercell's acquisition of IOMAI, the company's skin-targeted vaccine technology remained under development.

  Action taken

  The technology became the subject of a development license to GlaxoSmithKline.

  Aftermath

  The licensing arrangement extended the potential development and application of IOMAI's transcutaneous immunization technology through a major pharmaceutical company. The available sources do not provide later commercialization or financial details.

  Source

• 2008

  Intercell acquisitionM&A

  Background

  IOMAI had developed a specialized platform for transcutaneous immunization and had advanced a travelers' diarrhea vaccine patch through clinical development.

  Action taken

  Intercell acquired IOMAI and incorporated its technology and development activities into the acquiring company's vaccine portfolio.

  Aftermath

  IOMAI ceased to operate as an independent biotechnology company in the form described by the reference material. The technology continued to be considered for development and was subsequently licensed to GlaxoSmithKline.

  Source

1. 1IOMAIen.wikipedia.org
2. 2Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoeadoi.org
3. 3Transcutaneous immunization with the heat-labile toxin of enterotoxigenic E. colidoi.org
4. 4Safety and immunogenicity of an enterotoxigenic E. coli vaccine patchdoi.org
5. 5Safety and immunogenicity of an influenza vaccine coadministered with a heat-labile enterotoxin adjuvant patchdoi.org
6. 6Dose sparing with intradermal injection of influenza vaccinedoi.org